AIA Group Ltd Purchases Shares of 1,299 United Therapeutics Corporation $UTHR

AIA Group Ltd acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,299 shares of the biotechnology company’s stock, valued at approximately $545,000.

Several other large investors also recently made changes to their positions in UTHR. Allworth Financial LP lifted its stake in shares of United Therapeutics by 26.1% in the third quarter. Allworth Financial LP now owns 449 shares of the biotechnology company’s stock worth $188,000 after acquiring an additional 93 shares in the last quarter. Cambria Investment Management L.P. grew its stake in United Therapeutics by 20.9% during the 3rd quarter. Cambria Investment Management L.P. now owns 2,657 shares of the biotechnology company’s stock valued at $1,114,000 after purchasing an additional 460 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in United Therapeutics by 66.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 713 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 284 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in United Therapeutics during the 3rd quarter worth approximately $644,000. Finally, Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,938,901.40. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $529.59, for a total transaction of $5,031,105.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,455,279.67. The trade was a 19.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 347,320 shares of company stock worth $171,380,893. 10.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on UTHR. TD Cowen boosted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. UBS Group boosted their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Finally, Oppenheimer upped their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $548.09.

United Therapeutics Stock Performance

United Therapeutics stock opened at $524.28 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $548.12. The firm’s 50-day moving average is $490.39 and its 200-day moving average is $468.38. The company has a market cap of $22.98 billion, a P/E ratio of 18.79, a PEG ratio of 1.89 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned $6.19 earnings per share. As a group, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.